HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $485

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $470 to $485.